

QUALITY INCONTINENCE PRODUCTS IMPROVE SKIN OUTCOMES

Northwest Ohio Skilled Care Facility Trial



Introduction

In 2021 a Northwest Ohio Skilled Care Facility completed a Tranquility® product trial seeking to improve incontinence-related clinical outcomes. Amid record-high staff turnover rates the facility desired to improve resident outcomes in the areas of skin health (MASD/IAD) and incontinence-related pressure injuries (PI). The 30-day product trial included instruction on proper use of the products.

Trial Methods



30-day Trial



1 Unit



9 Residents

INDUSTRY STATISTICS ON PATIENT CARE

Prevalence of IAD¹

42% of hospitalized adults

83% of incontinent patients in ICUs

41% of residents in LTC facilities

Prevalence of Pressure Injuries²

17% of home health recipients

24% of skilled nursing residents

38% of hospitalized adults

MASD/IAD and PI Improvement

Several residents experiencing MASD (including IAD) in the buttock and sacral area were included in the trial, including one resident diagnosed with a stage 4 PI (images at right). During the trial period, the only change in staff protocols was the introduction and continued use of Tranquility incontinence products. There were no changes made to existing skin care or wound treatment protocols.

Resident Image - Day 1 of Trial (top)

Stage 4 PI in which healing was inhibited by prolonged periods of moisture against the skin, resulting in MASD (including IAD/periwound dermatitis).

Resident Image - Day 30 of Trial (bottom)

Following four weeks of using Tranquility incontinence products, the Stage 4 wound showed significant improvement including noticeable reduction in MASD, inflammation/redness and overall wound size.



Trial Conclusion

The results of the 30-day trial demonstrated that Tranquility superabsorbent products substantially improved resident skin health and pressure injuries.

- Improved Skin Health: Noticeable reductions in MASD and IAD.
 - **Zero new MASD cases were reported during a two-month period following full conversion to Tranquility.**
- Reduced Pressure Injuries: Residents experienced reduction in PI size and severity.
- Improved Resident/Staff Satisfaction: "The Tranquility products were amazing. To see the results of how our residents' wounds healed up and reduced redness was amazing. [The resident pictured] is completely healed of [the] pressure injury."

For more information about this clinical trial or Tranquility superabsorbent products, please contact us at 1-800-467-3224.

¹ Ermer-Seltun, J. (2011). Practical Prevention and Treatment of Incontinence-Associated Dermatitis — a Risk Factor for Pressure Ulcers. *Ostomy Wound Management*.
² Lyder C H, Ayello EA. Pressure Ulcers: A Patient Safety Issue. In: Hughes RG, editor. *Patient Safety and Quality: An Evidence-Based Handbook for Nurses*. Rockville (neD): Agency for Healthcare Research and Quality (US); 2008 Apr. Chapter 12 Available from: <http://www.ncbi.nlm.nih.gov/books/NBK2650/>